Calluna Pharma appoints Margrethe Sørgaard as senior VP

24 April 2024

Norway-based clinical-stage immunologics company Calluna Pharma today announced the appointment of Margrethe Sørgaard to the position of senior vice president of clinical operations and pharmacovigilance.

Ms Sørgaard joins the company’s cross-functional R&D team following Calluna’s launch, to oversee the strategic development of its clinical programs in line with regulatory guidelines and safety requirements.

Calluna is the result of a merger of Oxitope Pharma and Arxx Therapeutics announced in January, when the firm raised 75 million euros ($79.9 million) in a series A financing, to develop novel therapies for immunological diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK